{
  "articles": [
    {
      "pmid": "12345678",
      "title": "Metformin shows promise in NASH treatment",
      "authors": ["Smith J", "Kumar R"],
      "journal": "Nature Medicine",
      "year": 2024,
      "abstract": "A randomized study involving 200 NASH patients demonstrated that Metformin reduced hepatic steatosis and improved insulin sensitivity without major adverse effects.",
      "molecule": "Metformin",
      "disease": "NASH",
      "key_findings": "Reduced liver fat by 23%",
      "relevance_score": 0.92
    },
    {
      "pmid": "12345679",
      "title": "Metformin modulates gut microbiome in type 2 diabetes patients",
      "authors": ["Li W", "Johnson A"],
      "journal": "Diabetes Care",
      "year": 2023,
      "abstract": "This clinical investigation found that long-term Metformin use alters gut microbial composition, correlating with improved glycemic control.",
      "molecule": "Metformin",
      "disease": "Type 2 Diabetes",
      "key_findings": "Improved glycemic control via microbiome modulation",
      "relevance_score": 0.88
    },
    {
      "pmid": "12345680",
      "title": "Repurposing Metformin for cancer prevention: an overview",
      "authors": ["Garcia P", "Hernandez L"],
      "journal": "Oncology Reports",
      "year": 2022,
      "abstract": "Review of multiple clinical and preclinical studies indicating that Metformin may reduce cancer incidence, particularly in colorectal and breast cancer.",
      "molecule": "Metformin",
      "disease": "Cancer Prevention",
      "key_findings": "Potential chemopreventive effect via AMPK activation",
      "relevance_score": 0.85
    },
    {
      "pmid": "12345681",
      "title": "Aspirin use and cardiovascular outcomes in diabetic patients",
      "authors": ["Nguyen D", "Brown T"],
      "journal": "The Lancet",
      "year": 2023,
      "abstract": "Aspirin therapy significantly lowered the incidence of myocardial infarction and stroke among high-risk diabetic populations.",
      "molecule": "Aspirin",
      "disease": "Cardiovascular Disease",
      "key_findings": "Reduced MI risk by 18%",
      "relevance_score": 0.91
    },
    {
      "pmid": "12345682",
      "title": "Low-dose Aspirin in colorectal cancer prevention",
      "authors": ["Patel R", "Sato H"],
      "journal": "Journal of Clinical Oncology",
      "year": 2024,
      "abstract": "Low-dose aspirin correlated with reduced recurrence of colorectal adenomas in high-risk patients.",
      "molecule": "Aspirin",
      "disease": "Colorectal Cancer",
      "key_findings": "Reduced adenoma recurrence by 27%",
      "relevance_score": 0.89
    },
    {
      "pmid": "12345683",
      "title": "Aspirin and risk of intracranial bleeding: a meta-analysis",
      "authors": ["Zhou X", "Taylor M"],
      "journal": "BMJ",
      "year": 2021,
      "abstract": "Comprehensive meta-analysis evaluating bleeding risk associated with chronic low-dose aspirin use across 15,000 participants.",
      "molecule": "Aspirin",
      "disease": "Bleeding Risk",
      "key_findings": "Slight increase in bleeding risk (OR=1.14)",
      "relevance_score": 0.79
    },
    {
      "pmid": "12345684",
      "title": "Semaglutide efficacy in obesity management: a real-world study",
      "authors": ["Kaur P", "Anderson G"],
      "journal": "The New England Journal of Medicine",
      "year": 2024,
      "abstract": "A multicenter trial with 500 participants showed Semaglutide induced significant weight loss and improved lipid profiles.",
      "molecule": "Semaglutide",
      "disease": "Obesity",
      "key_findings": "Average 14.5% body weight reduction",
      "relevance_score": 0.95
    },
    {
      "pmid": "12345685",
      "title": "Semaglutide and cardiovascular outcomes in diabetic patients",
      "authors": ["Olsen L", "Fernandez P"],
      "journal": "Diabetologia",
      "year": 2023,
      "abstract": "Post-market analysis indicates cardiovascular benefit of Semaglutide independent of glycemic control improvement.",
      "molecule": "Semaglutide",
      "disease": "Type 2 Diabetes",
      "key_findings": "Reduced cardiovascular mortality by 22%",
      "relevance_score": 0.93
    },
    {
      "pmid": "12345686",
      "title": "Semaglutide as a potential therapy for NASH: insights from phase 2 trial",
      "authors": ["Kim D", "Hassan M"],
      "journal": "Hepatology",
      "year": 2024,
      "abstract": "A phase 2 clinical trial showed Semaglutide significantly reduced hepatic fat content and fibrosis progression in NASH patients.",
      "molecule": "Semaglutide",
      "disease": "NASH",
      "key_findings": "Histological improvement in 42% of patients",
      "relevance_score": 0.94
    },
    {
      "pmid": "12345687",
      "title": "Combination therapy of Semaglutide and Metformin in obese diabetic patients",
      "authors": ["Wang X", "Perez C"],
      "journal": "Endocrinology Today",
      "year": 2023,
      "abstract": "Combination of Semaglutide with Metformin showed synergistic effects in glycemic control and weight loss.",
      "molecule": "Semaglutide",
      "disease": "Type 2 Diabetes",
      "key_findings": "Enhanced HbA1c reduction compared to monotherapy",
      "relevance_score": 0.90
    },
    {
      "pmid": "12345688",
      "title": "Metformin and Semaglutide dual mechanism in NAFLD management",
      "authors": ["Singh A", "Lopez F"],
      "journal": "Journal of Hepatology",
      "year": 2025,
      "abstract": "Exploratory analysis suggests dual therapy may enhance hepatic lipid metabolism and reduce fibrosis in NAFLD.",
      "molecule": "Metformin, Semaglutide",
      "disease": "NAFLD",
      "key_findings": "Synergistic reduction in hepatic triglycerides",
      "relevance_score": 0.87
    },
    {
      "pmid": "FDA-001",
      "title": "FDA guidance on GLP-1 receptor agonists for metabolic disease",
      "authors": ["U.S. FDA"],
      "journal": "FDA Regulatory Bulletin",
      "year": 2024,
      "abstract": "Guidance outlines regulatory expectations for safety assessment of GLP-1 receptor agonists including Semaglutide in obesity and NASH.",
      "molecule": "Semaglutide",
      "disease": "Metabolic Diseases",
      "key_findings": "Long-term cardiovascular monitoring recommended",
      "relevance_score": 0.93,
      "type": "guideline"
    },
    {
      "pmid": "FDA-002",
      "title": "FDA guidance on repurposing antidiabetic agents for liver diseases",
      "authors": ["U.S. FDA"],
      "journal": "FDA Regulatory Bulletin",
      "year": 2023,
      "abstract": "Provides framework for clinical trial design when evaluating drugs like Metformin for new hepatic indications.",
      "molecule": "Metformin",
      "disease": "Liver Diseases",
      "key_findings": "Focus on adaptive trial design and safety endpoints",
      "relevance_score": 0.91,
      "type": "guideline"
    },
    {
      "pmid": "12345689",
      "title": "Metformin and inflammation markers in NASH patients",
      "authors": ["Ali R", "Bose S"],
      "journal": "Clinical Hepatology",
      "year": 2025,
      "abstract": "Metformin therapy reduced CRP and ALT levels, suggesting anti-inflammatory action beneficial in NASH.",
      "molecule": "Metformin",
      "disease": "NASH",
      "key_findings": "Decreased CRP levels by 31%",
      "relevance_score": 0.91
    },
    {
      "pmid": "12345690",
      "title": "Low-dose Aspirin and Alzheimer's prevention: a longitudinal study",
      "authors": ["Yamada T", "Singh R"],
      "journal": "Neurology Journal",
      "year": 2024,
      "abstract": "A 7-year observational study found reduced Alzheimer's incidence among low-dose aspirin users over 65.",
      "molecule": "Aspirin",
      "disease": "Alzheimerâ€™s Disease",
      "key_findings": "Risk reduction by 14%",
      "relevance_score": 0.84
    },
    {
      "pmid": "12345691",
      "title": "Semaglutide and renal outcomes: emerging evidence",
      "authors": ["Lee H", "Martinez C"],
      "journal": "Kidney International",
      "year": 2025,
      "abstract": "GLP-1 receptor agonists like Semaglutide show renoprotective effects in type 2 diabetic nephropathy.",
      "molecule": "Semaglutide",
      "disease": "Diabetic Nephropathy",
      "key_findings": "Reduced eGFR decline by 17%",
      "relevance_score": 0.89
    },
    {
      "pmid": "FDA-003",
      "title": "FDA safety update: monitoring requirements for metformin",
      "authors": ["U.S. FDA"],
      "journal": "FDA Bulletin",
      "year": 2025,
      "abstract": "Advisory regarding renal function monitoring in long-term Metformin users.",
      "molecule": "Metformin",
      "disease": "Type 2 Diabetes",
      "key_findings": "Annual renal assessment mandated",
      "relevance_score": 0.86,
      "type": "guideline"
    }
  ]
}
